Paper25947367
Impact of special patient populations on the pharmacokinetics of echinocandins.
Muilwijk EW and 6 others. Expert Rev Anti Infect Ther, 2015. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. Impact of special patient populations on the pharmacokinetics of echinocandins. Papers, record 25947367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25947367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antifungal Agents | Major topic |
| Echinocandins | Major topic |
| Lipopeptides | Major topic |
| Adolescent | |
| Adult | |
| Anidulafungin | |
| Candida | |
| Caspofungin | |
| Child | |
| Critical Illness | |
| Drug Interactions | |
| Hematologic Diseases | |
| Humans | |
| Infant, Newborn | |
| Kidney | |
| Liver | |
| Micafungin | |
| Microbial Sensitivity Tests | |
| Obesity |
Source PubMed
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40468532 | Prevalence of OATP1B-Mediated Drug-Drug Interactions in an Academic Medical Center. | Clin Transl Sci | 2025 | https://conductscience.org/library/papers/40468532 | PubMed |
| 38526051 | Updated antimicrobial dosing recommendations for obese patients. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/38526051 | PubMed |
| 36408257 | The recommended dosage regimen for caspofungin in patients with higher body weight or hypoalbuminaemia will result in low exposure: Five years of data based on a population pharmacokinetic model and Monte-Carlo simulations. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36408257 | PubMed |
| 35296203 | Echinocandins - structure, mechanism of action and use in antifungal therapy. | J Enzyme Inhib Med Chem | 2022 | https://conductscience.org/library/papers/35296203 | PubMed |
| 33404989 | Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis. | Pharm Res | 2021 | https://conductscience.org/library/papers/33404989 | PubMed |
| 33384549 | Invasive fungal infection before and after liver transplantation. | World J Gastroenterol | 2020 | https://conductscience.org/library/papers/33384549 | PubMed |
| 33333012 | Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. | Lancet Infect Dis | 2021 | https://conductscience.org/library/papers/33333012 | PubMed |
| 32672361 | Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis. | J Clin Pharm Ther | 2020 | https://conductscience.org/library/papers/32672361 | PubMed |
| 32667449 | Pharmacokinetics of micafungin in patients treated with extracorporeal membrane oxygenation: an observational prospective study. | Rev Bras Ter Intensiva | 2020 | https://conductscience.org/library/papers/32667449 | PubMed |
| 30150463 | Caspofungin Modulates Ryanodine Receptor-Mediated Calcium Release in Human Cardiac Myocytes. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/30150463 | PubMed |
| 29881298 | Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation. | Infect Drug Resist | 2018 | https://conductscience.org/library/papers/29881298 | PubMed |
| 29849129 | Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients. | Acta Pharmacol Sin | 2018 | https://conductscience.org/library/papers/29849129 | PubMed |
| 29551905 | Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis. | Infect Drug Resist | 2018 | https://conductscience.org/library/papers/29551905 | PubMed |
| 27820668 | New facets of antifungal therapy. | Virulence | 2017 | https://conductscience.org/library/papers/27820668 | PubMed |
| 27001813 | Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. | Antimicrob Agents Chemother | 2016 | https://conductscience.org/library/papers/27001813 | PubMed |
| 26503647 | Cardiac Effects of Echinocandins in Endotoxemic Rats. | Antimicrob Agents Chemother | 2016 | https://conductscience.org/library/papers/26503647 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25947367
GET https://conductscience.org/api/papers/v1/25947367/authors